2.81
0.20 (7.66%)
| Penutupan Terdahulu | 2.61 |
| Buka | 2.61 |
| Jumlah Dagangan | 190,989 |
| Purata Dagangan (3B) | 256,923 |
| Modal Pasaran | 16,417,413 |
| Harga / Buku (P/B) | 1.03 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 30 Mar 2026 |
| EPS Cair (TTM) | -0.780 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 56.38% |
| Nisbah Semasa (MRQ) | 0.540 |
| Aliran Tunai Operasi (OCF TTM) | -30.01 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -18.54 M |
| Pulangan Atas Aset (ROA TTM) | -178.72% |
| Pulangan Atas Ekuiti (ROE TTM) | -916.17% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Reviva Pharmaceuticals Holdings | Menurun | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | -3.5 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 0.5 |
| Purata Bergerak Teknikal | -2.5 |
| Osilator Teknikal | -2.5 |
| Purata | -2.00 |
|
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer’s disease and Parkinson’s disease psychosis and its other drug candidate is RP1208. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 10.30% |
| % Dimiliki oleh Institusi | 20.35% |
| Julat 52 Minggu | ||
| Median | 2.00 (-28.83%) | |
| Jumlah | 1 Beli | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Chardan Capital | 05 Jan 2026 | 2.00 (-28.83%) | Beli | 6.60 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 08 Jan 2026 | Pengumuman | Reviva Announces Publication on Clinical Vocal Biomarker Data from the RECOVER Phase 3 Clinical Trial of Brilaroxazine to Treat Negative Symptoms in Schizophrenia |
| 29 Dec 2025 | Pengumuman | Reviva to Present at the Sachs 9th Annual Neuroscience Innovation Forum |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |